Quality Id

Measure Name

High Priority

Measure Type

Measure Description

001

Diabetes: Hemoglobin A1c (HbA1c) Poor Control (>9%)

Yes

Intermediate Outcome

Percentage of patients 18-75 years of age with diabetes who had hemoglobin A1c > 9.0% during the measurement period

005

Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)

No

Process

Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed ACE inhibitor or ARB therapy either within a 12 month period when seen in the outpatient setting OR at each hospital discharge

006

Coronary Artery Disease (CAD): Antiplatelet Therapy

No

Process

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease (CAD) seen within a 12 month period who were prescribed aspirin or clopidogrel

007

Coronary Artery Disease (CAD): Beta-Blocker Therapy – Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF < 40%)

No

Process

Percentage of patients aged 18 years and older with a diagnosis of coronary artery disease seen within a 12-month period who also have a prior MI OR a current or prior LVEF <40% who were prescribed beta-blocker therapy

008

Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)

No

Process

Percentage of patients aged 18 years and older with a diagnosis of heart failure (HF) with a current or prior left ventricular ejection fraction (LVEF) < 40% who were prescribed beta-blocker therapy either within a 12-month period when seen in the outpatient setting OR at each hospital discharge

024

Communication with the Physician or Other Clinician Managing On-going Care Post-Fracture for Men and Women Aged 50 Years and Older

Yes

Process

Percentage of patients aged 50 years and older treated for a fracture with documentation of communication, between the physician treating the fracture and the physician or other clinician managing the patient’s on-going care, that a fracture occurred and that the patient was or should be considered for osteoporosis treatment or testing. This measure is reported by the physician who treats the fracture and who therefore is held accountable for the communication

039

Screening for Osteoporosis for Women Aged 65-85 Years of Age

No

Process

Percentage of female patients aged 65-85 years of age who ever had a central dual-energy X-ray absorptiometry (DXA) to check for osteoporosis

047

Care Plan

Yes

Process

Percentage of patients aged 65 years and older who have an advance care plan or surrogate decision maker documented in the medical record that an advance care plan was discussed but the patient did not wish or was not able to name a surrogate decision maker or provide an advance care plan

048

Urinary Incontinence: Assessment of Presence or Absence of Urinary Incontinence in Women Aged 65 Years and Older

No

Process

Percentage of female patients aged 65 years and older who were assessed for the presence or absence of urinary incontinence within 12 months

050

Urinary Incontinence: Plan of Care for Urinary Incontinence in Women Aged 65 Years and Older

Yes

Process

Percentage of female patients aged 65 years and older with a diagnosis of urinary incontinence with a documented plan of care for urinary incontinence at least once within 12 months

091

Acute Otitis Externa (AOE): Topical Therapy

No

Process

Percentage of patients aged 2 years and older with a diagnosis of AOE who were prescribed topical preparations

093

Acute Otitis Externa (AOE): Systemic Antimicrobial Therapy – Avoidance of Inappropriate Use

No

Process

Percentage of patients aged 2 years and older with a diagnosis of AOE who were not prescribed systemic antimicrobial therapy

117

Diabetes: Eye Exam

No

Process

Percentage of patients 18-75 years of age with diabetes who had a retinal or dilated eye exam by an eye care professional during the measurement period or a negative retinal exam (no evidence of retinopathy) in the 12 months prior to the measurement period

119

Diabetes: Medical Attention for Nephropathy

No

Process

The percentage of patients 18-75 years of age with diabetes who had a nephropathy screening test or evidence of nephropathy during the measurement period

126

Diabetes Mellitus: Diabetic Foot and Ankle Care, Peripheral Neuropathy – Neurological Evaluation

No

Process

Percentage of patients aged 18 years and older with a diagnosis of diabetes mellitus who had a neurological examination of their lower extremities within 12 months

128

Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan

No

Process

Percentage of patients aged 18 years and older with a BMI documented during the current encounter or during the previous twelve months AND with a BMI outside of normal parameters, a follow-up plan is documented during the encounter or during the previous twelve months of the current encounter 

Normal Parameters: 

Age 18 years and older BMI ≥ 18.5 and < 25 kg/m2

130

Documentation of Current Medications in the Medical Record

Yes

Process

Percentage of visits for patients aged 18 years and older for which the eligible professional or eligible clinician attests to documenting a list of current medications using all immediate resources available on the date of the encounter. This list must include ALL known prescriptions, over-the-counters, herbals, and vitamin/mineral/dietary (nutritional) supplements AND must contain the medications’ name, dosage, frequency and route of administration

134

Preventive Care and Screening: Screening for Depression and Follow-Up Plan

No

Process

Percentage of patients aged 12 years and older screened for depression on the date of the encounter using an age appropriate standardized depression screening tool AND if positive, a follow-up plan is documented on the date of the positive screen

154

Falls: Risk Assessment

Yes

Process

Percentage of patients aged 65 years and older with a history of falls that had a risk assessment for falls completed within 12 months

155

Falls: Plan of Care

Yes

Process

Percentage of patients aged 65 years and older with a history of falls that had a plan of care for falls documented within 12 months

181

Elder Maltreatment Screen and Follow-Up Plan

Yes

Process

Percentage of patients aged 65 years and older with a documented elder maltreatment screen using an Elder Maltreatment Screening Tool on the date of encounter AND a documented follow-up plan on the date of the positive screen

204

Ischemic Vascular Disease (IVD): Use of Aspirin or Another Antithrombotic

No

Process

Percentage of patients 18 years of age and older who were diagnosed with acute myocardial infarction (AMI), coronary artery bypass graft (CABG) or percutaneous coronary interventions (PCI) in the 12 months prior to the measurement period, or who had an active diagnosis of ischemic vascular disease (IVD) during the measurement period, and who had documentation of use of aspirin or another antiplatelet during the measurement period

226

Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention

No

Process

Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received tobacco cessation intervention if identified as a tobacco user

238

Use of High-Risk Medications in the Elderly

Yes

Process

Percentage of patients 65 years of age and older who were ordered high-risk medications. Two rates are submitted.
1) Percentage of patients who were ordered at least one high-risk medication.
2) Percentage of patients who were ordered at least two of the same high-risk medication

243

Cardiac Rehabilitation Patient Referral from an Outpatient Setting

Yes

Process

Percentage of patients evaluated in an outpatient setting who within the previous 12 months have experienced an acute myocardial infarction (MI), coronary artery bypass graft (CABG) surgery, a percutaneous coronary intervention (PCI), cardiac valve surgery, or cardiac transplantation, or who have chronic stable angina (CSA) and have not already participated in an early outpatient cardiac rehabilitation/secondary prevention (CR) program for the qualifying event/diagnosis who were referred to a CR program

317

Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented

No

Process

Percentage of patients aged 18 years and older seen during the submitting period who were screened for high blood pressure AND a recommended follow-up plan is documented based on the current blood pressure (BP) reading as indicated

326

Atrial Fibrillation and Atrial Flutter: Chronic Anticoagulation Therapy

No

Process

Percentage of patients aged 18 years and older with nonvalvular atrial fibrillation (AF) or atrial flutter who were prescribed warfarin OR another FDA- approved anticoagulant drug for the prevention of thromboembolism during the measurement period

331

Adult Sinusitis: Antibiotic Prescribed for Acute Viral Sinusitis (Overuse)

No

Process

Percentage of patients, aged 18 years and older, with a diagnosis of acute viral sinusitis who were prescribed an antibiotic within 10 days after onset of symptoms

332

Adult Sinusitis: Appropriate Choice of Antibiotic: Amoxicillin With or Without Clavulanate Prescribed for Patients with Acute Bacterial Sinusitis (Appropriate Use)

No

Process

Percentage of patients aged 18 years and older with a diagnosis of acute bacterial sinusitis that were prescribed amoxicillin, with or without clavulanate, as a first line antibiotic at the time of diagnosis

333

Adult Sinusitis: Computerized Tomography (CT) for Acute Sinusitis (Overuse)

No

Efficiency

Percentage of patients aged 18 years and older with a diagnosis of acute sinusitis who had a computerized tomography (CT) scan of the paranasal sinuses ordered at the time of diagnosis or received within 28 days after date of diagnosis

334

Adult Sinusitis: More than One Computerized Tomography (CT) Scan Within 90 Days for Chronic Sinusitis (Overuse)

No

Efficiency

Percentage of patients aged 18 years and older with a diagnosis of chronic sinusitis who had more than one CT scan of the paranasal sinuses ordered or received within 90 days after date of diagnosis

337

Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis Patients on a Biological Immune Response Modifier

No

Process

Percentage of patients whose providers are ensuring active tuberculosis prevention either through yearly negative standard tuberculosis screening tests or are reviewing the patient’s history to determine if they have had appropriate management for a recent or prior positive test

338

HIV Viral Load Suppression

Yes

Outcome

The percentage of patients, regardless of age, with a diagnosis of HIV with a HIV viral load less than 200 copies/mL at last HIV viral load test during the measurement year

342

Pain Brought Under Control Within 48 Hours

Yes

Outcome

Patients aged 18 and older who report being uncomfortable because of pain at the initial assessment (after admission to palliative care services) who report pain was brought to a comfortable level within 48 hours

370

Depression Remission at Twelve Months

Yes

Outcome

The percentage of patients 18 years of age and or older with major depression or dysthymia who reached remission 12 months (+/- 30 days) after an index visit

374

Closing the Referral Loop: Receipt of Specialist Report

Yes

Process

Percentage of patients with referrals, regardless of age, for which the referring provider receives a report from the provider to whom the patient was referred

383

Adherence to Antipsychotic Medications For Individuals with Schizophrenia

Yes

Intermediate Outcome

Percentage of individuals at least 18 years of age as of the beginning of the measurement period with schizophrenia or schizoaffective disorder who had at least two prescriptions filled for any antipsychotic medication and who had a Proportion of Days Covered (PDC) of at least 0.8 for antipsychotic medications during the measurement period (12 consecutive months)

387

Annual Hepatitis C Virus (HCV) Screening for Patients who are Active Injection Drug Users

No

Process

Percentage of patients, regardless of age, who are active injection drug users who received screening for HCV infection within the 12 month reporting period

398

Optimal Asthma Control

Yes

Outcome

Composite measure of the percentage of pediatric and adult patients whose asthma is well-controlled as demonstrated by one of three age appropriate patient reported outcome tools and not at risk for exacerbation

400

One-Time Screening for Hepatitis C Virus (HCV) for Patients at Risk

No

Process

Percentage of patients aged 18 years and older with one or more of the following: a history of injection drug use, receipt of a blood transfusion prior to 1992, receiving maintenance hemodialysis, OR birthdate in the years 1945-1965 who received one-time screening for hepatitis C virus (HCV) infection

401

Hepatitis C: Screening for Hepatocellular Carcinoma (HCC) in Patients with Cirrhosis

No

Process

Percentage of patients aged 18 years and older with a diagnosis of chronic hepatitis C cirrhosis who underwent imaging with either ultrasound, contrast enhanced CT or MRI for hepatocellular carcinoma (HCC) at least once within the 12 month reporting period

402

Tobacco Use and Help with Quitting Among Adolescents

No

Process

The percentage of adolescents 12 to 20 years of age with a primary care visit during the measurement year for whom tobacco use status was documented and received help with quitting if identified as a tobacco user

408

Opioid Therapy Follow-up Evaluation

No

Process

All patients 18 and older prescribed opiates for longer than six weeks duration who had a follow-up evaluation conducted at least every three months during Opioid Therapy documented in the medical record

412

Documentation of Signed Opioid Treatment Agreement

No

Process

All patients 18 and older prescribed opiates for longer than six weeks duration who signed an opioid treatment agreement at least once during Opioid Therapy documented in the medical record

414

Evaluation or Interview for Risk of Opioid Misuse

No

Process

All patients 18 and older prescribed opiates for longer than six weeks duration evaluated for risk of opioid misuse using a brief validated instrument (e.g. Opioid Risk Tool, SOAPP-R) or patient interview documented at least once during Opioid Therapy in the medical record

418

Osteoporosis Management in Women Who Had a Fracture

No

Process

The percentage of women age 50-85 who suffered a fracture and who either had a bone mineral density test or received a prescription for a drug to treat osteoporosis in the six months after the fracture

431

Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling

No

Process

Percentage of patients aged 18 years and older who were screened for unhealthy alcohol use using a systematic screening method at least once within the last 24 months AND who received brief counseling if identified as an unhealthy alcohol user

438

Statin Therapy for the Prevention and Treatment of Cardiovascular Disease

No

Process

Percentage of the following patients - all considered at high risk of cardiovascular events - who were prescribed or were on statin therapy during the measurement period:
• Adults aged ≥ 21 years who were previously diagnosed with or currently have an active diagnosis of clinical atherosclerotic cardiovascular disease (ASCVD); OR
• Adults aged ≥21 years who have ever had a fasting or direct low-density lipoprotein cholesterol (LDL-C) level ≥ 190 mg/dL; OR
• Adults aged 40-75 years with a diagnosis of diabetes with a fasting or direct LDL-C level of 70-189 mg/dL

441

Ischemic Vascular Disease (IVD) All or None Outcome Measure (Optimal Control)

Yes

Intermediate Outcome

The IVD All-or-None Measure is one outcome measure (optimal control). The measure contains four goals. All four goals within a measure must be reached in order to meet that measure. The numerator for the all-or-none measure should be collected from the organization's total IVD denominator. All-or-None Outcome Measure (Optimal Control) - Using the IVD denominator optimal results include: 
+G254
· Most recent blood pressure (BP) measurement is less than 140/90 mm Hg -- And 
· Most recent tobacco status is Tobacco Free -- And 
· Daily Aspirin or Other Antiplatelet Unless Contraindicated -- And 
· Statin Use Unless Contraindicated

442

Persistence of Beta-Blocker Treatment After a Heart Attack

No

Process

The percentage of patients 18 years of age and older during the measurement year who were hospitalized and discharged from July 1 of the year prior to the measurement year to June 30 of the measurement year with a diagnosis of acute myocardial infarction (AMI) and who were prescribed persistent beta-blocker treatment for six months after discharge

443

Non-Recommended Cervical Cancer Screening in Adolescent Females

No

Process

The percentage of adolescent females 16–20 years of age screened unnecessarily for cervical cancer

444

Medication Management for People with Asthma

Yes

Process

The percentage of patients 5-64 years of age during the measurement year who were identified as having persistent asthma and were dispensed appropriate medications that they remained on for at least 75% of their treatment period

447

Chlamydia Screening and Follow Up

No

Process

The percentage of female adolescents 16 years of age who had a chlamydia screening test with proper follow-up during the measurement period